Table 2.
Comparison of the results of the diagnostic tests between the first and second evaluation of subjects from a VL-endemic area
| Diagnostic test | First evaluation | Second evaluation | ||
|---|---|---|---|---|
| Total positive | Remained positive | Became positive | Total positive | |
| Positive | 122/246 (49.6%) | 105/122 (86.1%) | 51/124 (41.1%) | 156/246 (63.4%) |
| MST | 71/246 (28.9%) | 62/71 (87.3%) | 52/175 (29.7%) | 144/246 (46.3%) |
| TRALd | 31/246 (12.6%) | 3/31 (9.7%) | 2/215 (0.9%) | 5/246 (2.0%) |
| IIFT | 31/246 (12.6%) | 24/31 (77.4%) | 63/215 (29.3%) | 87/246 (35.4%) |
| ELISAp | 110/246 (44.7%) | 84/110 (76.4%) | 58/136 (42.7%) | 142/246 (57.7%) |
| ELISArk39 | 105/246 (42.7%) | 75/105 (71.4%) | 73/141 (51.8%) | 148/246 (60.2%) |
| ELISArk26 | 191/246 (77.6%) | 107/191 (56.0%) | 26/55 (47.3%) | 133/246 (54.1%) |
| Negative | 124/246 (50.4%) | 73/124 (58.9%) | 17/122 (13.9%) | 90/246 (36.6%) |
| MST | 175/246 (71.1%) | 123/175 (70.3%) | 9/71 (12.7%) | 132/246 (53.7%) |
| TRALd | 215/246 (87.4%) | 213/215 (99.1%) | 28/31 (90.3%) | 241/246 (98.0%) |
| IIFT | 215/246 (87.4%) | 152/215 (70.7%) | 7/31 (22.6%) | 159/246 (64.6%) |
| ELISAp | 136/246 (55.3%) | 78/136 (57.4%) | 26/110 (23.6%) | 104/246 (42.3%) |
| ELISArk39 | 141/246 (57.3%) | 68/141 (48.2%) | 30/105 (28.6%) | 98/246 (39.8%) |
| ELISArk26 | 55/246 (22.4%) | 29/55 (52.7%) | 84/191 (44.0%) | 113/246 (45.9%) |
McNemar test (P < 0.001 for all comparisons between first and second evaluation).